ReviewJournal of clinical medicine2025
Artificial Intelligence in Imaging for Personalized Management of Coronary Artery Disease.
Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Synthetic artificial intelligence in cardiology: from generative models to clinical applications.European heart journal open · 2026Review
- Brain metabolic imaging with 18 F-PET-CT and machine-learning clustering analysis reveal divergent metabolic phenotypes in patients with amyotrophic lateral sclerosis.European journal of nuclear medicine and molecular imaging · 2026Article
- Artificial Intelligence based fractional flow reserve.Cardiology journal · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The precision of imaging and the number of other risk-assessing and diagnostic methods are constantly growing, allowing for the uptake of additional strategies for individualized therapies. Personalized medicine has the potential to deliver more adequate treatment, resulting in better clinical outcomes, based on each patient's vulnerability or genetic makeup. In addition to increased efficiency, costs related to this type of procedure can be significantly lower. Useful assistance in designing individual therapies may be assured by the adoption of artificial intelligence (AI). Recent years have brought essential developments in deep and machine learning techniques. Advances in technologies such as convolutional neural networks (CNNs) have enabled automatic analyses of images, numerical data, and video data, providing high efficiency in the creation of prediction models. The number of AI applications in medicine is constantly growing, and the effectiveness of these techniques has been demonstrated in coronary computed tomography angiography (CCTA), optical coherence tomography (OCT), and many others. Moreover, AI models may be useful in direct therapy optimization for patients with coronary artery disease (CAD), who are burdened with high risk. The combination of well-trained AI with the design of individual treatment pathways can lead to improvements in health care. However, existing limitations, such as non-adapted guidelines or the lack of randomized clinical trials to evaluate AI's true accuracy, may contribute to delays in introducing automatic methods into practical use. This review critically appraises the developed tools that are potentially useful for clinicians in guiding personalized patient management, as well as current trials in this field.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.